MedTrace Logo

Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

NCT00495924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-07-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these.

Conditions

  • Pancreatic Neoplasms
  • Adenocarcinoma
  • Neoplasm Circulating Cells
  • Tumor Markers, Biological
  • Monitoring, Immunologic

Interventions

PROCEDURE

Pancreatic resection (PD)

PD is a standard therapeutic surgical procedure. No additional interventions are performed.

Sponsors & Collaborators

  • Research Foundation Flanders

    collaborator OTHER

  • Agentschap voor Innovatie door Wetenschap en Technologie

    collaborator OTHER

  • KU Leuven

    lead OTHER

Principal Investigators

  • Baki Topal, MD, PhD · Catholic University Leuven, Belgium

  • Gregory Sergeant, MD · Catholic University Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2008-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495924 on ClinicalTrials.gov